Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
Bharti Airtel Q4 Preview: PAT may jump up to 226% YoY on robust ARPU. Up to 35% revenue uptick seen
Bharti Airtel is set to reveal its Q4FY25 earnings on May 13. The telecom giant anticipates a significant surge in year-on-year profit. This growth is